RxDoctor Payments Data

Jeffrey Ridge

Family · McCloud, CANPI 1083180533

Payments from drug & device makers

$708in general payments, 2019–2025

Across 35 payments — averaging $20.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$248
  • AstraZeneca$143
  • Pfizer$80
  • Amgen$63
  • Exact Sciences$57
  • Gilead$44
  • plus $73 from 3 others

What the payments were for

  • Food & beverage$708100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$708 in reported general payments places this provider in the 65th percentile of 10,634 family providers in California.

See all family providers in California

Medicare billing

Part B allowed, 2024
$2,819
Medicare patients
155
Services billed
291

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban97$108,178
RybelsusSemaglutide68$67,674
TrulicityDulaglutide54$50,036
FarxigaDapagliflozin Propanediol67$48,018
OzempicSemaglutide39$39,180
JardianceEmpagliflozin37$31,189
Breztri AerosphereBudesonide/Glycopyr/Formoterol33$24,891
MounjaroTirzepatide21$22,303
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$22,098
Combivent RespimatIpratropium/Albuterol Sulfate27$19,364
Spiriva RespimatTiotropium Bromide23$14,371
XareltoRivaroxaban20$14,365
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog31$9,993
BelsomraSuvorexant22$9,217
Fluticasone-SalmeterolFluticasone Propion/Salmeterol22$6,043

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$80$108,17897 claims
Novo NordiskRybelsus, Ozempic$15$106,854107 claims
AstraZenecaFarxiga, Breztri Aerosphere$143$72,909100 claims
MerckBelsomra$18$9,21722 claims
AbbVieSynthroid$248$2,90122 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 10,634 family providers in California.

Other family in McCloud

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →